Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
22 studies found for:    Lupus AND Los Angeles | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Abatacept for SLE Arthritis (IM101-330)
Condition: Systemic Lupus Erythematosus Arthritis
Interventions: Drug: abatacept;   Drug: Placebo
2 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
3 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
4 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
5 Not yet recruiting MsciSLE: MSCs in SLE Trial
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Low Dose Mesenchymal Stem Cells (MSCs);   Drug: High Dose Mesenchymal Stem Cells (MSCs);   Drug: Placebo Infusion
6 Recruiting A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
7 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
8 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
9 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
10 Recruiting Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
11 Recruiting A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: RSLV-132;   Drug: Placebo
12 Recruiting Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Anifrolumab;   Drug: Placebo
13 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
14 Recruiting Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
15 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
16 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
17 Recruiting A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN)
Condition: Lupus Nephritis
Interventions: Drug: Mycophenolate Mofetil;   Drug: Obinutuzumab;   Drug: Placebo
18 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
19 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
20 Recruiting Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
Conditions: Autoimmune Disease;   Crohn Disease;   Inflammatory Disorder;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Takayasu Arteritis
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 Clofarabine;   Procedure: Positron Emission Tomography

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.